Childhood pneumococcal conjugate vaccine (PCV) protects against invasive pneumococcal disease caused by vaccine-serotype (VT) Streptococcus pneumoniae by generating opsonophagocytic anti-capsular... Show moreChildhood pneumococcal conjugate vaccine (PCV) protects against invasive pneumococcal disease caused by vaccine-serotype (VT) Streptococcus pneumoniae by generating opsonophagocytic anti-capsular antibodies, but how vaccination protects against and reduces VT carriage is less well understood. Using serological samples from PCV-vaccinated Malawian individuals and a UK human challenge model, we explored whether antibody quality (IgG subclass, opsonophagocytic killing, and avidity) is associated with protection from carriage. Following experimental challenge of adults with S. pneumoniae serotype 6B, 3/21 PCV13-vaccinees were colonised with pneumococcus compared to 12/24 hepatitis Avaccinated controls; PCV13-vaccination induced serotype-specific IgG, IgG1, and IgG2, and strong opsonophagocytic responses. However, there was no clear relationship between antibody quality and protection from carriage or carriage intensity after vaccination. Similarly, among PCV13-vaccinated Malawian infants there was no relationship between serotype-specific antibody titre or quality and carriage through exposure to circulating serotypes. Although opsonophagocytic responses were low in infants, antibody titre and avidity to circulating serotypes 19F and 6A were maintained or increased with age. These data suggest a complex relationship between antibody-mediated immunity and pneumococcal carriage, and that PCV13-driven antibody quality may mature with age and exposure. (c) 2022 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). Show less
Background and aimBiochar application to soil is widely claimed to increase plant productivity. However, the underlying mechanisms are still not conclusively described. Here, we aim to elucidate... Show moreBackground and aimBiochar application to soil is widely claimed to increase plant productivity. However, the underlying mechanisms are still not conclusively described. Here, we aim to elucidate these mechanisms using stable isotope probing.Methods We conducted two experiments with uniquely double-labelled (15N and 13C) biochar and its feedstock (residue), applied separately at 15 Mg ha−1. Both experiments contained three treatments: biochar amendment (Biochar), unpyrolysed residue amendment (Residue) and a no addition control (Control). Experiment I was a 119 day pot experiment seeded with Lolium perenne. Experiment II was a 71 day incubation experiment without plants in which CO2 and N2O fluxes were measured.Results Both Biochar and Residue significantly increased aboveground productivity compared to Control (140% and 160%, respectively). Initial N immobilisation was stimulated in Residue, whereas not in Biochar. 13C–CO2 analysis confirmed that biochar was significantly more recalcitrant than residue. 15N analysis showed that 2% and 0.3% of grass N was derived from the amended material in Residue and Biochar, respectively.ConclusionsOur results suggest that biochar-induced yield increases derive from a combination of reduced N immobilization and a moderate N fertilization effect. Although in the short term biochar might offer benefits compared to residue incorporation, it is unlikely that biochar yield gains will be sustainable for the decades to centuries that biochar C can be expected to reside in soil. Show less
Niu, M.; Heays, A.; Jones, S.; Salumbides, E.; Dishoeck, E.F. van; Oliveira, N. de; ... ; Ubachs, W. 2015
BACKGROUND: The Tamoxifen and Exemestane Adjuvant Multinational (TEAM) trial is an international randomized trial evaluating the efficacy and safety of exemestane, alone or following tamoxifen. The... Show moreBACKGROUND: The Tamoxifen and Exemestane Adjuvant Multinational (TEAM) trial is an international randomized trial evaluating the efficacy and safety of exemestane, alone or following tamoxifen. The large number of patients already recruited offered the opportunity to explore locoregional treatment practices between countries. METHODS: Patients were enrolled in Belgium, France, Germany, Greece, Ireland, Japan, the Netherlands, the UK and the USA. The core protocol had minor differences in eligibility criteria between countries, reflecting variations in national guidelines and practice regarding adjuvant endocrine therapy. RESULTS: Between 2001 and 2006, 9779 patients of mean(s.d.) age 64(9) years were randomized. Some 58.4 per cent had T1 tumours (range between countries 36.8-75.9 per cent; P < 0.001) and 47.3 per cent were axillary node positive (range 25.9-84.6 per cent; P < 0.001). Independent factors for type of breast surgery were country, age, tumour status and calendar year of surgery. After breast-conserving surgery, radiotherapy was given to 93.2 per cent of patients, 86.0 per cent in the USA and 100 per cent in France. Axillary lymph node dissection was performed in 82.0 (range 74.6-99.1) per cent. CONCLUSION: Despite international consensus guidelines, wide global variations were observed in treatment practices of early breast cancer. There should be further efforts to optimize locoregional treatment for breast cancer worldwide. Show less
